Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer
Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer
复制标题
DOI：
10.1007/s13277-011-0154-9
复制
发表时间：
2011-06-01
期刊：
影响因子：
--
通讯作者：
Gezer, Ugur
中科院分区：
文献类型：
--
作者：
Agaoglu, Fulya Yaman;Kovancilar, Muge;Gezer, Ugur
除了作为癌症分类和预测的组织标记物的潜力之外，血液循环中的 microRNA (miRNA) 的研究也令人感兴趣。在本研究中，我们调查了前列腺癌 (PCa) 患者血浆中三种与癌症相关的 miRNA（miR-21、-141 和 -221）的含量。该研究纳入了 51 名 PCa 患者的队列，并在两个亚组（局部/局部晚期或转移性 PCa）中测量了 miRNA。 20 名健康人作为对照组。使用 200 μl 血浆和小 RNA 分子 RNU1A 作为标准化循环中 miRNA 量的对照，对总 RNA 级分中的 miRNA 进行定量。我们发现健康受试者中三种 miRNA 的水平相似，中值分别为 0.039、0.033 和 0.04； （p = ns）。在患者中，miRNA 水平较高，其中 miR-21 最高（中位数为 1.51）。 miR-221 水平处于中等水平（中位数为 0.71），而 miR-141 的水平最低（中位数为 0.051）。对照组和患者之间的 miR-21（p < 0.001；曲线下面积 (AUC)，88%）和 -221（p < 0.001；AUC，83%）差异非常显着，但 miR-141 差异不显着（p = 0.2）。在诊断为转移性 PCa 的患者中，所有三种 miRNA 的水平均显着高于局部/局部晚期疾病患者，其中 miR-141 的差异最为明显（p < 0.001；AUC，75.5%）。总之，对 PCa 患者血液中 miR-21、-141 和 -221 的分析揭示了这些分子在 PCa 临床亚组中的不同模式。
In addition to their potential as tissue-based markers for cancer classification and prognostication, the study of microRNAs (miRNAs) in blood circulation is also of interest. In the present study, we investigated the amounts of three cancer-related miRNAs, miR-21, -141, and -221 in blood plasma of prostate cancer (PCa) patients. A cohort of 51 patients with PCa was enrolled into the study, and miRNAs were measured in two subgroups, with localized/local advanced or metastatic PCa. A group of 20 healthy individuals served as the control group. miRNAs were quantified from the total RNA fraction using 200 mu l plasma and the small RNA molecule RNU1A as a control for normalizing the miRNA amounts in circulation. We found similar levels of three miRNAs in healthy subjects with median values of 0.039, 0.033 and 0.04, respectively; (p = n.s.). In the patients, the miRNA levels were higher, with miR-21 being the highest (median, 1.51). The miR-221 levels were intermediate (median, 0.71) while the miR-141 displayed the lowest levels (median, 0.051). The differences between the control group and the patients were highly significant for the miR-21 (p < 0.001; area under the curve (AUC), 88%) and -221 (p < 0.001; AUC, 83%) but not for the miR-141 (p = 0.2). In patients diagnosed with metastatic PCa, levels of all three miRNAs were significantly higher than in patients with localized/local advanced disease where the difference for the miR-141 was most pronounced (p < 0.001; AUC, 75.5%). In conclusion, analysis of miR-21, -141, and -221 in blood of PCa patients reveals varying patterns of these molecules in clinical subgroups of PCa.